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Background: Myelodysplastic syndromes (MDS) are a group of heterogeneous diseases with variable clinical course.
Predicting disease progression is difficult due to lack of specific molecular marker(s). SALL4 plays important roles in normal
hematopoiesis and leukemogenesis. SALL4 transgenic mice develop MDS prior to acute myeloid leukemia (AML)
transformation. However, the role of SALL4 in human MDS has not been extensively investigated. In this study, we
evaluate the diagnostic/prognostic value of SALL4 in MDS by examining its expression levels in a cohort of MDS patients.
Methods: Fifty-five newly diagnosed MDS, twenty MDS-AML, and sixteen post-treatment MDS patients were selected for
our study along with ten healthy donors.
Results: We demonstrated that SALL4 was over-expressed in MDS patients and proportionally increased in MDS patients
with high grade/IPSS scores. This expression pattern was similar to that of Bmi-1, an important marker in predicting MDS/
AML progression. In addition, the level of SALL4 was positively correlated with increased blast counts, high-risk keryotypes
and increased significantly in MDS-AML transformation. Furthermore, higher level of SALL4 expression was associated
with worse survival rates and SALL4 level decreased following effective therapy.
Conclusions: To the best of our knowledge, this is the largest series and the first to report the expression pattern of
SALL4 in detail in various subtypes of MDS in comparison to that of Bmi-1. We conclude that SALL4 is a potential
molecular marker in predicting the prognosis of MDS.
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Myelodysplastic syndromes (MDS) are clonal hemato-
poietic stem cell (HSC) disorders characterized by refrac-
tory cytopenias with dysplasia as a result of ineffective
hematopoiesis [1]. Approximately 30 percent of MDS cases
progress to acute myeloid leukemia (AML) [2]. Excess
blasts are the strongest predictors for poor outcome and
are associated with disease progression [3]. Because of its
heterogeneity and lack of molecular markers that effectively
monitor disease progression, clinical management of MDS
patients is challenging. The International Prognostic Scor-
ing System (IPSS) is widely used to predict the prognosis* Correspondence: lchai@partners.org; cuiw@pumch.cn
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reproduction in any medium, provided the orof MDS [3,4], however, the prognostic information it pro-
vides is not always coincident with clinical outcome [5]. Re-
cently, a few genetic mutations and abnormal expressions
were reported to be involved in MDS pathogenesis and
showed potential clinical value [6-11].
SALL4 is an important embryonic stem cell (ESC) factor
that is also involved in normal hematopoiesis, leukemo-
genesis [12-20], hepatocellular carcinoma [21-23] and in-
fantile hemangiomas [24]. Due to its essential role for the
maintenance of pluripotent and self-renew of hemato-
poietic stem cell, SALL4 exhibits potential value in expan-
sion of hematopoietic stem cell in vitro [25-27]. We have
previously reported that SALL4 was constitutively ex-
pressed in human AML and SALL4 transgenic mice de-
veloped MDS–like features and subsequently AML [18].
We have also demonstrated recently that the expression
level of SALL4 was related to AML treatment status [16].
SALL4 had the highest expression level in untreated AMLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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remission (PR) and in complete remission (CR) patients.
Over-expression of SALL4 was also associated with drug
resistance. SALL4 expression levels declined during the
treatment process in the drug responsive group and in-
creased in the drug resistant group.
Bmi-1 is a member of the polycomb repression com-
plex, and is required for the maintenance and self-
renewal of normal and leukemic stem and progenitor
cells [28-30]. Our previous study linked Bmi-1 and
SALL4, showing Bmi-1 as a direct target gene of SALL4
in normal hematopoietic and leukemic cells [31]. SALL4
could bind to the Bmi-1 promoter; furthermore, induc-
tion of SALL4 expression was associated with increased
levels of histone H3–K4 and H3–K79 methylation in the
Bmi-1 promoter. Others [9] showed that Bmi-1 expres-
sion in CD34+ cells was high in refractory anemia with
excess blasts (RAEB), RAEB in transformation (RAEB-
T), and MDS-AML. The expression level of Bmi-1 was
correlated with IPSS score, suggesting that Bmi-1 can be
a potential marker for predicting the prognosis of MDS.
Since MDS is a pre-leukemic stage of AML [32] and
the expression pattern of SALL4 in human MDS hasn’t
been intensively investigated, in this study we evaluate
the expression of SALL4 in various MDS patients com-
pared to that of Bmi-1 to explore the potential clinical
prognostic value of SALL4 in MDS.
Results
The expression of SALL4 was increased in MDS patients
and correlated with disease progression and treatment
status
We first evaluated the expression of SALL4 in primary
MDS patients by analyzing MDS gene expression pro-
files from the public database GSE13159 [33]. The dataFigure 1 SALL4 expression was increased in MDS patients and correla
expression levels by microarray in 206 MDS cohort (GSE13159). The data w
expression in the healthy control, MDS, MDS-AML, MDS-post treatment and
***p-value<0.001. The lines indicate mean value of each group.was presented as log-transformed scaled signal (DS sig-
nal) [34]. We noticed that SALL4 expression measured
by microarray was higher (p<0.001) in MDS patients
(88.49±77.57, n=206) than that from normal controls
(50.54±34.13, n=73) (Figure 1A).
We next chose 55 newly diagnosed MDS patients, 20
MDS-AML patients and 16 post-treatment MDS patients
for our study and the clinicopathological profile of these
patients was summarized in Table 1. The expression level
of each gene was presented as 2-ΔΔCT relative quantitative
values. Our results demonstrated that SALL4 mRNA ex-
pression level in MDS patients (23.88±21.59, n=55) was
significantly higher (p<0.001) than that from the healthy
control group (1.02±0.19, n=10). Furthermore, SALL4 ex-
pression increased significantly (p<0.001) in MDS-AML
(AML patients with history of MDS) patients (74.35±
20.00, n=20), but deceased (p<0.05) in post-treatment
MDS patients (4.66±4.43, n=16) (Figure 1B).
SALL4 and Bmi-1 shared a similar expression pattern in
human MDS with both expressions increased in
high-grade morphology and high IPSS score cases
Because MDS is a group of heterogeneous diseases, differ-
ent subtypes and risk groups exhibit great heterogeneities.
We next evaluated SALL4 expression in different WHO
morphology and IPSS risk groups and compared expres-
sion with that of Bmi-1. Between different MDS subtypes
by WHO classification, the expression of SALL4 was sig-
nificantly higher (p<0.001) in RAEB-1 (35.06±16.32, n=14)
and RAEB-2 (45.66±16.87, n=13) subtypes when compared
with healthy control, but not refractory cytopenia (RA)
(6.62±7.21, n=18) or refractory cytopenia with multilineage
dysplasia (RCMD) (8.95±9.72, n=10). Similarly, higher
(p<0.001) expression of Bmi-1 was also preferentially seen
in RAEB-1 (22.47±11.89, n=14) and RAEB-2 (33.92±19.00,ted with disease progression and treatment status. (A) SALL4
as presented as log-transformed scaled signal (DS signal). (B) SALL4
THP-1 positive control analyzed by qRT-PCR. * P-value<0.05,
Table 1 Characteristics of patients with MDS, MDS-AML and MDS post-treatment
MDS MDS-AML MDS post-
treatmentRA RCMD RAEB-1 RAEB-2
Patients (N) 18 10 14 13 20 16
Gender
Male 5 6 9 7 10 10
Female 13 4 5 6 10 6
Age (year)
Median 36 48.5 69 65 68.5 53
Range 22-72 20-77 52-81 25-82 28-82 22-74
BM Blast (%)
Median 1 1.75 6.5 15.5 55 0.75
Range 0-3.5 0.5-4.5 5-8.5 11-19.5 23-98 0-7.5
Karyotype (N)*
Good 14 7 7 4 5 13
Intermediate 4 2 2 0 3 3
Poor 0 1 5 9 12 0
IPSS score
Median 0.5 0.5 1.25 3 –– ––
Range 0-1 0-1.5 1-2 2-3 –– ––
*Karyotype: Good=normal, -Y alone, del(5q) alone, del(20q) alone; Poor=complex (≥3 abnormalities) or chromosome 7 abnormalies;
Intermediate=other abnormalities.
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of MDS based on IPSS, Int-1 (11.19±10.35, n=25), Int-2
(40.97±12.36, n=12) and High risk groups (52.37±15.65,
n=9) had higher (p<0.05) SALL4 expressions than healthy
control. As for Bmi-1 expression, Int-2 (28.77±13.00,
n=12) and High risk group (36.77±18.97, n=9) showed sig-
nificantly higher (p<0.001) levels than healthy control
(Figure 2B). Furthermore, we performed western blots to
see SALL4 and Bmi-1 expression on protein level and
found that the protein expression of these two genes
followed the same trend (Figure 2C). However, semi-
quantitatively analysis demonstrated that this trend was
statistically significant for SALL4 (p<0.01) but not Bmi-1
(p>0.05) (Figure 2D).
SALL4 expression was correlated with blast counts, IPSS
score, Bmi-1 and poor cytogenetic characters
To investigate the potential value of SALL4 in the clin-
ical diagnostic application of MDS patients, we next
conducted Spearman’s correlation analysis on the mRNA
expression of SALL4 and clinical parameters. Our results
showed that SALL4 was positively correlated with bone
marrow blast counts, IPSS score and expression level of
Bmi-1 (Table 2). In addition, we observed that SALL4
expression was higher (p<0.001) in MDS patients with
high risk (50.14±14.44, n=15) karyotypes according to
IPSS, including complex karyotypes (n=14) and chromo-
some 7 abnormalities (n=1), but lower (p<0.001) inpatients with intermediate (15.53±18.62, n=8) and low
risk (13.02±11.51, n=32) karyotypes (Figure 3).
MDS patients with high SALL4 expression showed disease
progression and worse survival
During our over 2 years’ follow-up, 11 of 27 (40.74%)
RAEB-1/RAEB-2 patients experience disease progres-
sion. SALL4 expression of these cases (54.27±14.71,
n=11) was significantly higher (p<0.01) than those with-
out disease progression (30.47±10.89, n=16). 14 patients
died of MDS or AML progressed from MDS. Since both
IPSS and WHO have been used to guide clinical diag-
nosis and management of MDS patients, we first con-
ducted Kaplan-Meier survival analysis for MDS patients
based on WHO subtypes and IPSS risk groups. Based on
WHO subtypes, the RAEB-2 group that showed high
SALL4 and Bmi-1 expression had a worse (p<0.01) sur-
vival rate than other subtypes (Figure 4A). Based on
IPSS risk groups, Int-2 and High risk patient groups
whose SALL4 and Bmi-1 expression levels were higher
than that from Int-1 and Low risk patient groups
exhibited a worse (p<0.01) survival rate (Figure 4B). In-
triguingly, we noted that among the Int-2 risk group, pa-
tients who passed away during the follow up (53.42±
11.25, 4 of 12) had higher (p=0.0056) SALL4 expres-
sion than those who were still alive at the end of the
study (34.75±7.82, 8 of 12). This trend was also observed
for Bmi-1 expression. Patients who passed away in the
Figure 2 SALL4 and Bmi-1 shared a similar expression pattern in MDS: both were increased in high-grade morphology and high IPSS
score cases. (A) SALL4 and Bmi-1 expression in subtypes of MDS according to WHO classification. (B) SALL4 and Bmi-1 expression in different
IPSS risk groups. (C) Representative SALL4 and Bmi-1 protein expression analyzed by western blot. The protein expression of SALL4 in RAEB-1/
RAEB-2 was higher than that of healthy control. Bmi-1 protein expression followed a similar trend. THP-1 cell line was used as a positive
control. (D) Semi-quantitatively analysis demonstrated that this trend was statistically significant for SALL4 but not for Bmi-1. * P-value<0.05,
**p-value<0.01, ***p-value<0.001, ns: no significance. The lines indicate mean value of each group.
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Table 2 Spearman correlation analysis between SALL4
and clinical parameters in MDS patients
Clinical parameters Correlation coefficient (rs) p - value
SALL4 vs. BM blast (%) 0.802 <0.001
SALL4 vs. IPSS score 0.808 <0.001
SALL4 vs. Bmi-1 0.790 <0.001
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4.78, 4 of 12), while patients who were still alive had
lower Bmi-1 expression (27.69±15.87, 8 of 12). How-
ever, this difference was not significant (p=0.7058).
We further conducted Kaplan-Meier survival analysis
for MDS patients based on Bmi-1 or SALL4 expression
level (The group with high Bmi-1 or SALL4 expression
had Bmi-1 or SALL4 mRNA expression that was equal
to or exceeded the mean value detected by qRT-PCR,
where as the group with low Bmi-1 or SALL4 expression
had Bmi-1 or SALL4 mRNA expression that was lower
than the mean value). MDS patients with high Bmi-1 or
SALL4 expression levels showed a worse (p<0.01) sur-
vival rate than low Bmi-1 or SALL4 group (Figure 4C-
D). These results suggest that SALL4 and/or Bmi-1
expression could be used as an additional confirmation/
refinement for the WHO/IPSS system or even as single
or combined molecular tests to help predict the progno-
sis of MDS. More detailed analysis, however, showed
minor differences between the Bmi-1 and SALL4 expres-
sion in the survival rate of MDS patients. There was noFigure 3 SALL4 expression was correlated with cytogenetic
characters. SALL4 expression in MDS patients with high-risk
karyotypes was significantly higher than patients with intermediate
and low karyotypes, however there was no significant difference
between patients with intermediate and low karyotypes. The risk
classification of karyotypes was based on IPSS. ***P-value<0.001, ns:
no significance. The lines indicate mean value of each group.patient death with low SALL4 expression (Figure 4D), but
3 patients died with low Bmi-1 expression (Figure 4C).
This result suggested that SALL4 might be a better mo-
lecular marker than Bmi-1, in predicting MDS patient
prognosis; however a large cohort study is needed to con-
firm this result.
Discussion
In this study we have examined the expression levels of
stem cell factor SALL4 in MDS patients from various
MDS morphology subtypes and IPSS risk groups in
comparison to Bmi-1 expression levels in these patients.
Our study showed that SALL4 expression was high in
newly diagnosed MDS patients and increased signifi-
cantly in MDS-AML patients, but deceased in post-
treatment MDS patients. Higher SALL4 expression was
seen in MDS patients with high grade/IPSS scores, an
expression pattern similar to that of Bmi-1. We have
also evaluated the correlation between SALL4 expression
and several clinical parameters such as bone marrow
blast count, karyotype and IPSS scores. This cohort of
MDS patients was followed up with for about two years.
We noticed that MDS patients with high SALL4 expres-
sion had a worse survival rate. When taken together, our
study results suggest that SALL4 can be used as a poten-
tial new molecular marker in predicting the prognosis of
MDS. To our knowledge, this is the first study to analyze
SALL4 prognostic value in MDS patients.
Recently another study reported a significant positive
correlation between the level of SALL4 transcript and the
status of SALL4 hypomethylation in MDS patients [35].
They also found that the patients in higher IPSS risk
groups (Int-2/High) and WHO classifications had signifi-
cantly higher incidence of SALL4 hypomethylation than
those in low risk groups (Low/Int-1) and mild WHO clas-
sifications. It remains to be determined whether hypo-
methylation is a mechanism for aberrant high SALL4
expression in MDS patients with higher IPSS risks and
WHO subtypes.
One unique feature of our MDS patient cohort is that
the median age of these patients is only 56 (from 20 to
82), which is younger than most reported median ages
for MDS patients. This may be due to the fact that in
China, most patients pay for their own medical care ex-
penses, and younger patients will seek medical care
more readily than older patients due to underlying
social-economical reasons.
In our study, SALL4 expression is related to several clin-
ical parameters. For example, bone marrow blast count,
an important factor that contributes to WHO categories
and IPSS risk groups, was positively related to SALL4 ex-
pression level. This finding was in agreement with previ-
ous studies that demonstrated that SALL4 was expressed
preferentially in normal purified CD34+ hematopoietic
Figure 4 MDS patients with high SALL4 expression had worse survival rates. (A) Kaplan-Meier survival curves for MDS patients based on
WHO subtypes. The RAEB-2 group with higher SALL4 and Bmi-1 expression levels showed a worse survival rate. (B) Kaplan-Meier survival curves
for MDS patients based on IPSS risk groups. Int-2 and High risk groups had worse survival rates than Int-1 and Low risk groups. Correspondingly,
SALL4 and Bmi-1 expression levels were also higher in Int-2 and High risk groups. (C) Kaplan-Meier survival curves for MDS patients based on
Bmi-1 expression level. (D) Kaplan-Meier survival curves for MDS patients based on SALL4 expression level. *P-value<0.05 analyzed by log-rank
test. The expression data on SALL4 and Bim-1 were presented as mean±SD.
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and B-cell lymphoblastic leukemia/lymphomas [13-15,18].
This also explained why SALL4 expression in MDS was
lower than that from MDS-AML as mentioned above. In
this study, we have also evaluated SALL4 expression and
its correlation with cytogenetic abnormalities. Cytogenetic
abnormalities have been found at diagnosis in 20-70% of
MDS patients, especially in RAEB-1/RAEB-2 cases [1,36],
and are critical in evaluating the outcome of patients with
MDS. In our study, we observed that SALL4 was highly
expressed in MDS patients with complex karyotypes and
chromosome 7 abnormalities. Further study is needed to
investigate whether high SALL4 expression contributes
to chromosome disability or is the result of complex
phenotype.
Our survival analysis demonstrated that MDS patients
with higher SALL4 expression had a worse survival rate.
Intriguingly, in our study, most of the MDS patients that
died were from IPSS High/Int-2 risk or WHO RAEB-1/2
groups except one case, which was classified as WHO
RA subtype with an IPSS score of Int-1 risk group. How-
ever, the SALL4 expression of this patient was as high as
33.50 at the time of diagnosis. Because the patient was
diagnosed with RA/Int-1 risk, only supportive treatment
was provided. This patient passed away 18 months after-
ward. Though this is only one case and a larger study
size is needed, it seems to suggest that SALL4 expression
could be used at least as an additional confirmation/re-
finement for the IPSS/WHO system to help predict the
prognosis of MDS, and to confirm high-risk patients can
get proper treatment as soon as possible.
Conclusions
In summary, we are the first to report the expression pat-
tern of SALL4, an embryonic stem cell factor and a
leukemic survival factor, in various morphological sub-
types and risk groups of MDS along with a comparison to
Bmi-1. Our study suggests that SALL4 can be used as a
potential molecular marker in predicting poor prognosis
of MDS. Furthermore, qRT-PCR, a simple test to evaluate
SALL4 expression, is a good and measurable proxy for
bone marrow blast cell count which is notoriously difficult
to standardize. Though a future prospective study with a
large group of patients is required to further evaluate our
observations, our results suggest that SALL4 expression
level can potentially be used to guide decision making in
the treatment of MDS patients.
Methods
Cells
THP-1 Human Monocytic Leukemia Cells (Cell Center,
Institute of Basic Medical Sciences, Chinese Academy of
Science) were cultured in RPMI 1640 supplemented with
10% fetal bovine serum.Patients and control samples
Bone marrow samples from 55 newly diagnosed MDS pa-
tients, 20 MDS-AML patients, 16 post-treatment MDS pa-
tients and 10 healthy donors were collected in Beijing from
December 2009 to December 2011. This study was ap-
proved by the institutional review board of Peking Union
Medical College Hospital. The diagnosis of MDS was based
on the 2008 World Health Organization (WHO) Classifi-
cation [37]. Patients with low or Int-1 IPSS risk received
clinical monitoring and relevant supportive care. In
general, patients with symptomatic anemia or severe
thrombocytopia were treated with relative transfusion. Re-
combinant human Epo with or without recombinant hu-
man granulocyte colony stimulating factor (G-CSF) were
used for patients with serum erythropoietin (EPO) levels ≤
500mU/ml. Azacytidine or decitabine were used for pa-
tients with thrombocytopenia or neutropenia. For patients
with del (5q) chromosomal abnormalities, Lenadomide
was used for treatment. Int-2 or high risk patients received
high intensive therapy including intensive chemotherapy
(such as azacytidine and decitabine) or allogeneic hema-
topoietic stem cell transplantation (HSCT) if available. For
patients who were not suitable (e.g., patient’s age, perform-
ance status and patient’s preference) for intensive therapy,
relative supportive care was given. Bone marrow samples
from post-treatment MDS patients were collected after the
patients completed at least two-course treatment.
The 206-MDS-cohort was downloaded from Gene Ex-
pression Omnibus (GEO) dataset [38] under series ac-
cession number GSE13159. The data in this microarray
was presented as log-transformed scaled signal (DS
signal) [34].
Isolation of bone marrow nucleated cells
Red blood cell lysis buffer was used to isolate nucleated
cells from bone marrow samples according to a standard
procedure. The isolated nucleated cells were then di-
vided into two parts, one of which was conducted with
Trizol reagent (Invitrogen) for RNA analysis, the other
of which was processed with Cell Lysis Buffer (Beyotime
Biotchnology, China) for further protein analysis.
Quantitative-reverse-transcription-polymerase-chain-
reaction (qRT-PCR)
Total RNA was extracted with Trizol reagent (Invitrogen)
and treated with DNase. Reverse transcription and PCR
amplification were performed according to manufacturer’s
instruction (DRR036 and DRR091, TaKaRa). All of the re-
actions were run in triplicate. The expression level of each
gene was normalized to the housekeeping gene β-actin
and analyzed by 2-ΔΔCT relative quantitative method. The
sequences of primers were as follows: SALL4 (amplicon
length, 68bp; targated Exon2 of human SALL4), forward
primer 5′-TGCAGCAGTTGGTGGAGAAC-3′, reverse
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1 (amplicon length, 198 bp), forward primer 5′-TGGACT
GACAAATGCTGGAGA-3′, reverse primer 5′-GAAGA
TTGGTGGTTACCGCTG-3′; β-actin (amplicon length,
124 bp), forward primer 5′-TGTACGCCAACACAGTG
CTG-3′, reverse primer 5′-TCAGGAGGAGCAATGA
TCTTG-3′.
Western blot
Western blot was performed according to standard tech-
niques. The following antibodies were used: SALL4
(ab29112, Abcam), Bmi-1 (05–637, Mlillipore), and β-
actin (TA-09, ZSGB-BIO, China). The dilution ratio of
SALL4 was 1:1000, Bmi-1 1:1000 and β-actin 1:2000.
Statistical analyses
Statistical analyses were performed using SPSS software
package Version 12.0. P-values of <0.05 were considered
statistically significant. Data were presented as means ±
standard deviation. Unpaired t-test or Mann–Whitney
test was used to study difference between two groups.
One-Way ANOVA or Kruskal-Wallis test were applied
to study differences between more than two groups.
When significance was found, Bonferroni’s multiple
comparison test or Dunnett’s multiple comparison test
was used as a post hoc test. Correlation analysis was
performed using the Spearman’s rank correlation coeffi-
cient rs. Survival curves were constructed using the
Kaplan-Meier method and compared using the log-rank
test.
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